INNOVIVA, INC.

INVA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $271.2M $23.4M $179.7M $220.3M $368.8M $293.8M $191.0M $406.3M
Depreciation & Amortization $13.8M $13.8M $13.9M $13.9M
Depreciation
Amortization $26.3M $25.9M $21.8M $5.6M $0 $0
Stock-Based Compensation $9.5M $6.4M $5.8M $7.3M $2.0M $1.7M $2.1M $3.2M
Net Cash from Operating Activities $196.9M $188.7M $141.1M $201.7M $363.8M $313.1M $257.5M $223.5M
Investing Activities
Capital Expenditures $1.1M $270.0K $411.0K $67.0K $0 $13.0K $12.0K $0
Business Acquisitions
Net Cash from Investing Activities $40.5M $-63.8M $-66.8M $-56.6M $43.7M $-314.9M $-18.0M $3.5M
Financing Activities
Dividends Paid $0 $0 $11.0K $80.0K
Stock Repurchases $4.5M $14.8M $75.7M $8.5M $394.1M $0 $0 $0
Net Cash from Financing Activities $8.6M $-13.5M $-171.8M $-55.6M $-452.5M $-29.8M $-23.8M $-238.0M
Net Change in Cash $246.0M $111.5M $-97.5M $89.5M $-45.0M $-31.6M $215.7M $-10.9M
Free Cash Flow $195.8M $188.4M $140.7M $201.7M $363.8M $313.1M $257.4M $223.5M
← Newer Page 1 of 3 Older →